These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9205982)

  • 41. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients.
    Spivey JF; Singleton D; Sweet S; Storch GA; Hayashi RJ; Huddleston CB; Danziger-Isakov LA
    Pediatr Transplant; 2007 May; 11(3):312-8. PubMed ID: 17430489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.
    Kirklin JK; Naftel DC; Levine TB; Bourge RC; Pelletier GB; O'Donnell J; Miller LW; Pritzker MR
    J Heart Lung Transplant; 1994; 13(3):394-404. PubMed ID: 8061014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
    Snydman DR; Kistler KD; Ulsh P; Morris J
    Transplantation; 2010 Dec; 90(12):1432-8. PubMed ID: 21076378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
    Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of cytomegalovirus in cardiac allograft vasculopathy.
    Weill D
    Transpl Infect Dis; 2001; 3 Suppl 2():44-8. PubMed ID: 11926750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
    Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
    Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients.
    Lee SO; Rim JH; Sung H; Kim SH; Choi SH; Lee CW; Yun TJ; Lee JW; Woo JH; Kim YS; Kim JJ
    Transpl Infect Dis; 2010 Feb; 12(1):31-7. PubMed ID: 19843292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.
    Johanssson I; Mårtensson G; Andersson R
    Scand J Infect Dis; 2010; 42(2):129-36. PubMed ID: 20082575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation.
    Ciancio G; Burke GW; Mattiazzi A; Leibovici Z; Dowdy L; Roth D; Kupin W; Rosen A; Jorge D; Cirocco RE; Miller J
    Clin Transplant; 2004 Aug; 18(4):402-6. PubMed ID: 15233817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
    Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma of donor-positive/recipient-negative serostatus.
    Avery RK
    Clin Infect Dis; 2007 Aug; 45(4):448-9. PubMed ID: 17638192
    [No Abstract]   [Full Text] [Related]  

  • 58. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
    Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
    Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.